Compare ETON & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | FEIM |
|---|---|---|
| Founded | 2017 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 348.4M |
| IPO Year | 2018 | N/A |
| Metric | ETON | FEIM |
|---|---|---|
| Price | $16.84 | $46.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $29.67 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 277.8K | 253.9K |
| Earning Date | 11-06-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 163.74 |
| EPS | N/A | ★ 2.17 |
| Revenue | ★ $70,316,000.00 | $69,852,000.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | $17.90 |
| P/E Ratio | ★ N/A | $21.44 |
| Revenue Growth | ★ 102.77 | 16.06 |
| 52 Week Low | $11.09 | $13.69 |
| 52 Week High | $23.00 | $48.35 |
| Indicator | ETON | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 80.83 |
| Support Level | $16.13 | $27.32 |
| Resistance Level | $17.05 | $36.48 |
| Average True Range (ATR) | 0.76 | 2.55 |
| MACD | 0.16 | 1.86 |
| Stochastic Oscillator | 79.06 | 95.56 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.